Board of Directors

At Flagship Pioneering, which he founded in 2000, Noubar has created an enterprise where entrepreneurially minded scientists invent seemingly unreasonable solutions to challenges facing human health and sustainability. They begin by asking “What if?” and iterate toward the unexpected answer “It turns out,” resulting in the creation of first-in-category companies with significant impact. Flagship has fostered the development of more than 100 scientific ventures resulting in $30 billion in aggregate value, thousands of patents and patent applications, and more than 50 drugs in clinical development.

During his career as inventor, entrepreneur, and CEO, Noubar has co-founded and helped build over 40 life sciences and technology startups. Prior to founding Flagship Pioneering, Noubar was the founder and CEO of PerSeptive Biosystems, a leader in bio-instrumentation that grew to $100 million in annual revenues. After PerSeptive’s acquisition by Perkin Elmer/Applera Corporation in 1998, he became senior vice president and chief business officer of Applera, where he initiated and oversaw the creation of Celera Genomics.

He serves on the boards of a number of public and private Flagship companies, including Moderna (NASDAQ: MRNA), where he is chairman and Rubius Therapeutics (NASDAQ: RUBY). Previously, he was a member of the founding team, director, and investor in highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millenium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb), and Affinnova (acquired by AC Nielsen).

Noubar entered biotechnology during its emergence as an academic field and industry, completing his doctoral work in biochemical engineering at MIT in 1987. He has written numerous scientific publications and has been granted approximately 100 patents. He is a lecturer at Harvard Business School, and from 2000 to 2016 was a senior lecturer at MIT’s Sloan School of Management. He teaches and speaks around the world on topics ranging from entrepreneurship, innovation, and economic development to biological engineering, new medicines, and renewable energy.

Noubar’s commitment to improving the human condition through science and business goes hand in hand with social investments and a global humanitarian initiative. Together with his partners in Flagship, he has launched philanthropic projects including the IDeA Foundation, UWC Dilijan School, 100 LIVES, and the Aurora Prize for Awakening Humanity, which seeks to raise awareness of the world’s most pressing humanitarian problems. Noubar is a member of the Corporation of MIT (the Institute’s governing body) and a member of the board of overseers for the Boston Symphony Orchestra.

Noubar was born in Beirut to Armenian parents in 1962, did his undergraduate work at McGill University in Montreal, and completed his PhD in biochemical engineering at MIT in 1987. A passionate advocate of the contributions of immigrants to economic and scientific progress, Noubar received the Golden Door Award in 2017 from the International Institute of New England, in honor of his outstanding contributions to American society as a U.S citizen of foreign birth. He was also awarded a Great Immigrant honor from the Carnegie Corporation in 2016, received a Technology Pioneer award from the World Economic Forum in 2012, and was presented with the Ellis Island Medal of Honor in 2008.

Frances received the Nobel Prize in Chemistry (2018) for pioneering directed enzyme evolution; she has used those methods to create enzymes for alternative energy, chemicals, and medicine. Frances received the Charles Stark Draper Prize of the U.S. National Academy of Engineering in 2011, the U.S. National Medal of Technology and Innovation from President Obama in 2013, and the Millennium Technology Prize in 2016. She has been elected to all three of the U.S. National Academies of Science, Medicine, and Engineering. She was appointed by Pope Francis to the Pontifical Academy of Sciences in 2019.

Co-inventor on 58 issued U.S. patents and active in technology transfer, Frances co-founded Gevo, Inc., in 2005 to make fuels and chemicals from renewable resources; Provivi, Inc., in 2014 to develop non-toxic modes of agricultural pest control; and Aralez, Inc., in 2019 to develop sustainable biocatalytic processes for producing medicines and chemicals. Frances received her BS in mechanical and aerospace engineering from Princeton University and her PhD in Chemical engineering from the University of California, Berkeley. She chairs the Advisory Panel of the David and Lucile Packard Foundation Fellowships in Science and Engineering and is a trustee of the Gordon Research Conferences.

Stéphane has served as Moderna’s chief executive officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the company, Mr. Bancel served for five years as chief executive officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as managing director for Belgium and as executive director of global manufacturing strategy and supply chain. Prior to his work at Lilly, Stéphane served as Asia-Pacific sales and marketing director for bioMérieux.

Stéphane currently serves on the board of directors of Generate:Biomedicines and Qiagen N.V., and he previously served on the boards of BG Medicine, Inc. and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is a venture partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Stéphane holds a master of engineering degree from École Centrale Paris (ECP), a master’s of science in chemical engineering from the University of Minnesota, and an MBA from Harvard Business School.

From 2000 to 2009, Marsha held several executive leadership roles at Millennium Pharmaceuticals, including chief financial officer, senior vice president of strategy, vice president of finance and strategy, and vice president of corporate development and strategy. She helped lead Millennium to profitability and played a central role in the company’s $8.8 billion acquisition by Takeda Pharmaceutical Company in 2008.

Earlier in her career, she served as vice president of corporate development and strategy at Genzyme Corporation and as vice president and director at Arthur D. Little.

Marsha has previously served on the boards of Alnylam Pharmaceuticals, Momenta Pharmaceuticals, Ironwood Pharmaceuticals, Cyclerion Therapeutics, Forma Therapeutics, and Syros Pharmaceuticals.

She earned a Bachelor of Science in Pharmacy from West Virginia University and an MBA from Northeastern University.

Jane spent over 20 years working at the Yale Investment Office, the Harvard Management Company and then Wellesley College in various roles managing their endowments and investments. In 2008, she returned to Harvard as Chief Executive Officer of the management company, where she was responsible for the university’s approximately $37 billion global endowment and related assets for six years. Under her leadership, Harvard became the first university endowment to join the PRI, a United Nations-supported network of investors committed to promoting sustainable investments by incorporating environmental, social and governance factors into investment decision-making.

Jane has received many honors, including the 100 Women in Hedge Funds 2007 Leadership Award for her “talent, ethics and passion, which help define the industry’s standard of excellence.” She was also named one of Forbes 100 Most Powerful Women in 2008 and 2009. Jane received her bachelor of arts degree from Yale College and her master’s of business administration from the Yale School of Management.

Since his appointment in 2021, Mike has helped lead Generate:Biomedicines’ growth as it pioneers Generative Biology®. During his tenure, the company completed its Series B and C financing rounds and raised more than $750 million prior to its initial public offering. In 2026, Generate completed its IPO, raising approximately $400 million to advance its platform and pipeline. These funding milestones have enabled continued investment in the company’s generative AI platform and a growing pipeline of protein therapeutics, including five clinical-stage molecules and multiple additional preclinical programs.

Mike has also been instrumental in forging significant partnerships with leading institutions, laying a strong foundation for future advancement. For example, in 2022, the company announced a collaboration with Amgen focused on developing protein therapies, which was later expanded in January 2024. Additionally, in 2023, Generate:Biomedicines announced strategic collaborations with the MD Anderson Cancer Center and Roswell Park Comprehensive Cancer Center, which aim to harness their respective strengths in specialized medical research and treatment modalities to deliver novel therapeutics in oncology and CAR-T cells respectively.

Before joining Generate:Biomedicines, Mike held several key leadership positions at Merck & Co., Inc. As Chief Marketing Officer, he was responsible for the Global Marketing and Brand Strategy of a diverse portfolio encompassing innovative medicines and vaccines, generating over $40 billion in revenue. His previous roles at Merck & Co. include serving as President of Global Vaccines and managing the company’s operations in Sweden and the UK.

In addition to his executive role at Generate:Biomedicines, Mike serves on the boards of Expedition Medicines, Harbinger Health, and PPG Industries. At PPG Industries, he is a member of the Audit Committee and the Sustainability and Innovation Committee.

Mike holds an MBA from Harvard Business School, a degree in Accounting and Finance from the London School of Economics, and a BA in Economics from Middlebury College.

Paul leads all capital solutions efforts at Flagship, driving portfolio value realization, fundraising activities, and building and managing Flagship’s relationships with Limited Partners as well as strategic and financial investors. He also plays a key role on Flagship’s senior leadership team, helping drive value, impact, and effectiveness across the organization.

Paul brings over 35 years of experience in banking, pharma and biotech, as well as in mergers and acquisitions (M&A), corporate strategy, and organizational leadership. He has worked across multiple sectors and geographies, built and managed several multi-billion-dollar businesses, and led teams of several thousand employees.

Prior to joining Flagship, Paul was a Corporate Officer, member of the Company Leadership Team, and served as Senior Vice President, Strategy and Corporate Development for Thermo Fisher Scientific. In this capacity he held a number of enterprise-level operating roles, including having responsibility for Corporate Strategy, Corporate Development, Strategic Capital, Integration Management, Corporate Social Responsibility, and Government Relations. He previously served as Co-Chairman of the Global Mergers and Acquisitions Group for Goldman Sachs & Co. and served on the firm’s Partnership Committee and the Investment Banking Senior Leadership Council. Prior to Goldman Sachs, Paul held senior positions at Barclays Group Plc where he served as Chairman and Head of Global M&A, subsequently adding responsibilities as Co-Head of Corporate Finance. He was previously an investment banker at Lehman Brothers in several senior leadership positions, ultimately serving as Chairman and Head of Global M&A. Earlier in his career, Parker held positions at other financial institutions, including J.P. Morgan & Co.

Paul previously served as a Board member of The Clorox Company from 2020-2024.

He earned an MBA with distinction from Harvard Business School and a bachelor’s degree in international studies from the University of North Carolina at Chapel Hill.

Prior to Syros, Nancy was Chief Medical Officer at Millennium Pharmaceuticals and Vice President of Clinical Development at Biogen. At Millennium, Nancy oversaw the successful development of VELCADE to treat multiple myeloma and mantle cell lymphoma, NINLARO to treat multiple myeloma and ENTYVIO to treat inflammatory bowel disease. At Biogen, she played a central role in developing AVONEX and TYSABRI for multiple sclerosis.

Nancy started her career as an assistant professor at Harvard Medical School and Massachusetts General Hospital (MGH). She trained in medicine and neurology at MGH, received an M.D. from the University of Pennsylvania, and a B.A. in biology from Princeton. She currently serves as a director of the board of Alltrna (private company), the supervisory board of Bayer AG (BAYR) and the Damon Runyon Cancer Research Foundation. She previously served as a director of Syros (NASDAQ: SYRS), Seagen (NASDAQ: SGEN; acquired by Pfizer in 2023), Evelo (NASDAQ: EVLO) and Arqule (NASDAQ: ARQL; acquired by Merck in 2020).

Previously, Rupert served as Executive Vice President and President, Research for Bristol Myers Squibb (BMS). He joined BMS with its acquisition of Celgene in 2019. In this role, he led Research, overseeing the advancement of promising programs, technologies and assets across all therapeutic areas, from discovery through proof-of-concept. He also worked closely with Business Development to identify external sources of innovation. In addition, he served as the executive sponsor of the Organization for Latino Achievement (OLA) People and Business Resource Group and the Bristol Myers Squibb STEM Council.

Rupert joined BMS from Celgene, where he served as president of the company’s Research and Early Development organization. Prior to joining Celgene in 2015, Rupert spent 10 years at Merck, where he was responsible for numerous drug development programs and held leadership roles in the company’s Early Development, Discovery Sciences, Drug Discovery and Informatics groups, as well as its respiratory and immunology franchise. Prior to his time at Merck, he spent five years at GlaxoSmithKline involved in drug discovery, experimental medicine and early clinical development of therapeutics for respiratory and immune diseases.

Rupert graduated from Oxford University in the United Kingdom with degrees in physiological sciences (M.A.), clinical medicine (B.M., B.Ch.) and a Doctor of Philosophy (DPhil) in molecular immunology. He is an elected fellow of the Royal College of Physicians.